Caplin Point Laboratories Ltd
Caplin Point Laboratories Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #18 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Caplin Point expects continued strong growth in pharmaceutical sales, particularly in Latin America and the US. Caplin Point Laboratories expects sustained strong growth over the next 3-5 years, considered their best period ahead.
From Caplin Point Laboratories Ltd's Q4 FY26 earnings-call transcript · updated 3 Sept 2026.
Revenue & Sales Performance
- Caplin Point expects continued strong growth in pharmaceutical sales, particularly in Latin America and the US.
- Latin America growth may stabilize for 12-18 months due to regulatory product development timelines but is expected to rebound strongly thereafter.
- In the next 18-24 months, overall growth in Latin America sales is anticipated to return to double-digit rates.
- The US business is projected to sustain 20-25% growth driven by new ANDA approvals and expanding own-label products.
- Caplin Steriles business expects around 25-30% growth next year.
- Chile and Mexico markets are poised for significant expansion with increased product registrations and distribution.
- The company targets nearly doubling own-label sales from INR 100 crores to close to INR 200 crores in the coming year.
2 more points from Caplin Point Laboratories Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Caplin Point Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Residual capex of approximately INR 510 crores to be spent over the next 18-24 months, part of a larger INR 1,100 crores capex plan (50% completed).
- Ongoing projects include:
- Phase-III of injectable plant (POL-2).
- Construction of a larger capacity oral solids and derma facility in Pondicherry.
- Completion of oncology API plant.
- Plans for new facilities/buildings in Mexico and Chile, with execution starting by Q3 or Q4.
- Capex does not yet include inorganic growth plans like acquisitions or new warehouses/quality control labs in international markets.
- Despite ongoing capex, reserves and surplus are expected to continue rising due to strong cash generation.
2 more points from Caplin Point Laboratories Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Caplin Point Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Caplin Point Laboratories has a full order book for nearly six months.
- The company is seeing strong demand with no dearth of orders currently.
- Some lower-margin, high-volume products are being selectively declined to maintain profitability.
- Tender supplies, such as the large one in El Salvador (valued at about $16 million), have contributed to recent growth and increased receivables.
2 more points from Caplin Point Laboratories Ltd's call on order book
Create a free account to keep reading this call
Caplin Point Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹600 Cr, net profit ₹173 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Caplin Point Laboratories Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharmaceuticals Ltd (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals Ltd (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Caplin Point Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Caplin Point Laboratories Ltd Q4 FY26 results?
Caplin Point expects continued strong growth in pharmaceutical sales, particularly in Latin America and the US. Caplin Point Laboratories expects sustained strong growth over the next 3-5 years, considered their best period ahead.
What is Caplin Point Laboratories Ltd share price analysis?
Caplin Point Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 29.3 with a market cap of ₹19,465 Cr. Investors should review the full earnings analysis for detailed insights.
Is Caplin Point Laboratories Ltd planning capital expenditure?
Residual capex of approximately INR 510 crores to be spent over the next 18-24 months, part of a larger INR 1,100 crores capex plan (50% completed).
Keep Caplin Point Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.